#

Pharmaceutical Companies

: 153
The company listed on NASDAQ under the ticker symbol BLSM. Photo: BlossomHill
News·
BlossomHill Therapeutics IPO: Cancer Drug Developer Goes Public
Photo: Seacalm/Shutterstock
News·
Braveheart Bio IPO: Shares in the cardiovascular drug developer are now available
Eli Lilly Raises Forecast Thanks to the Success of Its Weight-Loss Drugs / Photo: Tada Image / Shutterstock.com
News·
Lilly raised its revenue forecast. This eased fears that the weight-loss boom is on the decline
Novo Nordisk shares fell after the company reported disappointing sales results for its weight-loss drug / Photo: Shutterstock.com / Kittyfly
News·
Weak sales of Wegovy overshadowed Novo's "clearly less-than-impressive" forecast revision
Shares of AstraZeneca, a British biopharmaceutical giant, fell nearly 7%. Photo: Mats Wiklund/Shutterstock
News·
AstraZeneca shares plummeted following news of a mega-deal with Bristol Myers
The failure of Novo Nordisks drug trials sent its stock tumbling 10% / Photo: JHVEPhoto / Shutterstock
News·
Novo Nordisk shares plummeted 10% after a heart drug trial failed
Novo Nordisk shareholders have succeeded in securing the launch of a judicial investigation into the results of testing for the drug CagriSema / Photo: gguy / Shutterstock
News·
Novo Will Sue Investors Over the Results of a Study on a Weight-Loss Drug
Hedge funds have increased their exposure to healthcare stocks to a nearly five-year high
News·
Hedge funds have increased their exposure to healthcare stocks to a nearly five-year high
Profits at British pharmaceutical giant AstraZeneca exceeded analysts expectations last quarter. Photo: Konektus Photo/Shutterstock
News·
Oncology drugs helped boost AstraZeneca's profits by 21%. Will the company expand its portfolio?
Pharmaceutical giant Eli Lilly is a shareholder of Scribe / Photo: sasirin pamai / Shutterstock
News·
IPO Scribe: Shares in a biotech company backed by Eli Lilly and Sanofi are now available
The transaction gives Eli Lilly access to AtaiBeckley’s experimental drug being studied in phase III clinical trials for treatment-resistant depression / Photo: Shutterstock.com / Tada Images
News·
+1
·
Eli Lilly officially to acquire psychedelics drugmaker AtaiBeckley for $3.8 bln
Biogen shares fell following the release of results from Phase 2 trials of an Alzheimers drug / Photo: Shutterstock.com / JHVEPhoto
News·
Biogen shares fell after disappointing data on its Alzheimer's drug
Load more